BR0002933A - Tratamento para complicações diabéticas - Google Patents

Tratamento para complicações diabéticas

Info

Publication number
BR0002933A
BR0002933A BR0002933-5A BR0002933A BR0002933A BR 0002933 A BR0002933 A BR 0002933A BR 0002933 A BR0002933 A BR 0002933A BR 0002933 A BR0002933 A BR 0002933A
Authority
BR
Brazil
Prior art keywords
diabetic
treatment
prodrug
inhibitor
diabetic complications
Prior art date
Application number
BR0002933-5A
Other languages
English (en)
Inventor
Banavara Lakshman Mylari
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0002933A publication Critical patent/BR0002933A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: <B>"TRATAMENTO PARA COMPLICAçõES DIABéTICAS"<D>. A invenção refere-se a métodos, composições farmacêuticas e "kits" compreendendo um inibidor da aldose redutase (ARI), uma sua pró-droga ou um sal farmaceuticamente aceitável do referido ARI ou referida pró-droga e um inibidor seletivo de COX-2, uma sua pró-droga ou um sal farmaceuticamente aceitável do referido inibidor seletivo de COX-2 ou pró-droga. Esta invenção ainda refere-se a métodos de utilização destas composições farmacêuticas para o tratamento de complicações diabéticas tais como neuropatia diabética, nefropatia diabética, retinopatia diabética, enfarte miocardial, cataratas e cardiomiopatia diabética.
BR0002933-5A 1999-06-30 2000-06-30 Tratamento para complicações diabéticas BR0002933A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14178099P 1999-06-30 1999-06-30

Publications (1)

Publication Number Publication Date
BR0002933A true BR0002933A (pt) 2001-01-30

Family

ID=22497220

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0002933-5A BR0002933A (pt) 1999-06-30 2000-06-30 Tratamento para complicações diabéticas

Country Status (5)

Country Link
US (1) US6426341B1 (pt)
EP (1) EP1064949A3 (pt)
JP (1) JP2001031589A (pt)
BR (1) BR0002933A (pt)
CA (1) CA2313105A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555540B1 (en) * 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
US7935726B1 (en) 1999-11-12 2011-05-03 Kansas State University Research Foundation Tricyclic pyrones
AR030346A1 (es) 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
IL157935A0 (en) * 2001-04-30 2004-03-28 Pfizer Prod Inc Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
WO2002098462A1 (fr) * 2001-06-01 2002-12-12 Ono Pharmaceutical Co., Ltd. Remedes contenant un inhibiteur d'aldose reductase en tant qu'agent actif destines a des troubles de demyelinisation ou des troubles associes a la demyelinisation
WO2005049014A1 (en) * 2003-11-18 2005-06-02 Pharmacia Corporation Cox-2 inhibitors for the treatment or prevention of diabetes-related ocular disorders
DK1719774T3 (da) * 2004-01-30 2012-07-16 Sanwa Kagaku Kenkyusho Co Terapeutisk middel mod diabetisk makulaødem
CA2633481C (en) * 2005-12-16 2013-12-17 Sanwa Kagaku Kenkyusho Co., Ltd. Preventive or therapeutic agent for acute renal failure
EP2220216A4 (en) * 2007-11-15 2013-03-20 Univ Laval PROCESS FOR REGULATING THE PROSTAGLANDIN F-SYNTHASE (PGFS) ACTIVITY OF AKR1B1 AND USES THEREOF

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
ES2201466T3 (es) * 1997-03-14 2004-03-16 MERCK FROSST CANADA &amp; CO. `(metilsulfonil)fenil-2-(5h)-furanonas con enlace con oxigeno como inhibidores de cox-2`.
IL124236A (en) * 1997-05-05 2003-01-12 Pfizer Pharmaceutical composition for treating or reversing diabetic cardiomyopathy comprising aldose reductase inhibitor
GB9714274D0 (en) * 1997-07-08 1997-09-10 Zeneca Ltd Pharmaceutical composition
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
US6555540B1 (en) * 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
US6413965B1 (en) * 1999-06-30 2002-07-02 Pfizer Inc. Compositions and treatment for diabetic complications
US6673818B2 (en) * 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation

Also Published As

Publication number Publication date
EP1064949A2 (en) 2001-01-03
EP1064949A3 (en) 2003-02-26
US6426341B1 (en) 2002-07-30
JP2001031589A (ja) 2001-02-06
CA2313105A1 (en) 2000-12-30

Similar Documents

Publication Publication Date Title
BR0002953A (pt) Composições e tratamento para complicações diabéticas
BR0005765A (pt) Combinação de inibidores de aldose redutase e agentes anti-hipertensivos para o tratamento de complicações diabéticas
BR0313233A (pt) Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, e, composição farmacêutica
BR9913912A (pt) Métodos e composições para tratamento de doenças mediadas por receptor
AU2003268156A1 (en) Novel pyrazolopyridine derivatves as pharmaceutical agents
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
MA29568B1 (fr) Composes d&#39;azaindazole et methodes d&#39;utilisation desdits composes
UA96115C2 (uk) Спосіб і композиція для лікування амілоїдогенних захворювань
DK1292335T3 (da) Kombinationer og sammensætninger, som interfererer med VEGF/VEGF og angiopoietin/Tie receptor funktion og deres anvendelse (II)
BRPI0715579A2 (pt) &#34;composto, composição farmacêutica e uso de um composto&#34;
MA29088B1 (fr) Composes d&#39;indazole-carboxamide.
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
BR0316583A (pt) Derivados de ácido acético 3-alquil e 3-arilalquil 1h-indol-1-il substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
BR0211502A (pt) Derivados de ácido acético de indano e seu uso como agentes farmacêuticos, intermediários, e método de preparação
BR0105457A (pt) Combinações terapêuticas para estimulação do crescimento ósseo
WO2005121778A3 (en) Methods for identification, and compounds useful for the treatment of degenerative &amp; inflammatory diseases
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
SE0101932D0 (sv) Pharmaceutical combinations
BR0313385A (pt) Derivados de pirimidina-2,4-diona como inibidores de metaloproteinase da matriz
PT1325011E (pt) Metodos e compostos para tratamento de doencas proliferativas
BR0002933A (pt) Tratamento para complicações diabéticas
WO2007075177A3 (en) Antibiotics targeting mreb
EP1106184A3 (en) Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
MXPA05008960A (es) Oxazolidinonas de indolona antibacteriales, intermedios para su preparacion y composiciones farmaceuticas que las contienen.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7O, 8O E 9O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI2003 DE 26/05/2009.